- Home
- ATRA vs ALGS Comparison
ATRA vs ALGS Comparison
Compare ATRA & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | ALGS |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 37.1M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATRA | ALGS |
|---|---|---|
| Price | $4.83 | $6.46 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.00 | ★ $39.33 |
| AVG Volume (30 Days) | 58.9K | ★ 202.7K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | 88.30 |
| EPS | ★ 2.57 | N/A |
| Revenue | ★ $120,772,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | $1.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.92 | $4.20 |
| 52 Week High | $19.15 | $13.69 |
Technical Indicators
Market Signals| Indicator | ATRA | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 44.00 |
| Support Level | $4.70 | $6.25 |
| Resistance Level | $5.47 | $8.30 |
| Average True Range (ATR) | 0.31 | 0.53 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 30.67 | 18.18 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.